Merck profit beats on Keytruda strength, raises full-year forecast

Drugmaker Merck & Co on Friday raised its full-year profit forecast after beating Wall Street estimates for quarterly profit as sales of blockbuster cancer drug Keytruda nearly doubled.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News